Immunotherapy cocktail aims to boost immune attack on prostate tumors before surgery
NCT ID NCT03821246
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radical prostatectomy. The goal is to see if these combinations increase tumor-fighting T cells, potentially improving outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab (Tecentriq), tocilizumab (Actemra), etrumadenant (AB928)
What this could lead to
If successful, this could point toward a new way to shrink prostate tumors before surgery, potentially reducing recurrence risk.
What could go wrong
This is an early phase 2 trial with only 68 participants, so results may not apply broadly. The primary endpoint is a biomarker (immune cell increase), not a direct cure or survival benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alvin J. Siteman Cancer Center at Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••